Business
REGENXBIO Announces Presentations at the 19th Annual WORLDSymposium™ 2023
New interim data from Phase I/I/III trial of RGX-121 for the treatment of MPS II and Phase I/II trial of RGX-111 for the treatment of MPS I to be
About this update from Regenxbio Inc.
[{"type":"text","content":"New interim data from Phase I/I/III trial of RGX-121 for the treatment of MPS II and Phase I/II trial of RGX-111 for the treatment of MPS I to be presentedROCKVILLE, Md., Feb. 17, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral and eight poster presentations will be presented at the 19th Annual WORLDSymposium™ 2023, taking place in Orlando, Florida from February 22 through 26, 2023. The presentations include new interim results from the Phase I/II/III clinical trial of RGX-121 for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome, and the Phase I/II trial of RGX-111 for the treatment of severe mucopolysaccharidosis type I (MPS I).\nREGENXBIO will also host a sponsored symposium session, titled \"AAV Gene Therapy as a Potential Treatment Modality for Neuronopathic MPS II\" on Friday, February 24, 2023, at 11:45 a.m. ET.\nThe oral presentations will be presented as follows:\nAbstract Title: RGX-111 gene therapy for the treatment of severe mucopolysaccharidosis type I (MPS I): Interim analysis of data from the first in human study (abstract #191)Presenter: Raymond Wang, M.D., Division of Metabolic Disorders, CHOC Children's Hospital, Department of Pediatrics, University of California, Irvine, CADate/Time: Friday, February 24, 2023, 9:24 a.m. ET\nAbstract Title: In vitro pharmacology study using retina organoids and retina-on-a-chip of CLN2 patient-derived induced pluripotent stem cells (abstract #311, also available as poster #201)Presenter: Kwi Hye Kim, Ph.D., Principal Scientist, Preclinical Development at REGENXBIO Inc.Date/Time: Saturday, February 25, 2023, 2:48 p.m. ET\nAbstract Title: RGX-121 gene therapy for the treatment of neuronopathic mucopolysaccharidosis type II (MPS II): Interim analysis of data from the first in human study (abstract #LB-21)Presenter: Can Ficicioglu, M.D., Ph.D., Professor of Pediatrics at Perelman School of Medicine at the University of Pennsylvania, Director of the Newborn Metabolic Screening Program and the Lysosomal Storage Diseases Program, Clinical Director of the Metabolic Disease Program Children's Hospital of PhiladelphiaDate/Time: Sunday, February 26, 2023, 9 a.m. ET (also available as an ePoster Wednesday, February 22, 2023, 3 p.m. ET)\nThe poster presentations will be presented as follows:\nAbstract Title: Spontaneous...